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Introduction
Cell commitment and differentiation involves the carefully 
  regulated expression of genes associated with terminal differen-
tiation, and many different biological systems have been used 
to identify the factors and networks that regulate these genes. 
Skeletal myogenesis represents a particularly well-studied 
model system (Tapscott, 2005). Vertebrate skeletal myogenesis 
is regulated by a family of four related basic helix-loop-helix 
transcription factors: Myf5, MyoD, Myog, and Mrf4 (Molkentin 
and Olson, 1996; Puri and Sartorelli, 2000; Pownall et al., 2002; 
Buckingham et al., 2003). Recent studies indicate that MyoD, 
and perhaps by analogy Myf5, binds to promoters of genes 
  expressed throughout the program of myogenesis, establishing 
temporal patterning through feed-forward mechanisms with 
other regulatory factors (Bergstrom et al., 2002; Penn et al., 
2004; Cao et al., 2006). An interesting and relatively unstudied 
feature of the MyoD-mediated differentiation program, how-
ever, is the suppression of the nonmuscle phenotype in cells that 
are converted to skeletal muscle by MyoD. For example, ex-
pression of MyoD in melanocytes, adipocytes, and chon drocytes 
results not only in the positive regulation of skeletal   muscle 
genes, but also in the suppression of molecular phenotypes specifi  c 
to the melanocyte, adipocyte, and chondrocyte, respectively 
(Weintraub et al., 1989; Choi et al., 1990). In this regard, conver-
sion of a cell to skeletal muscle by MyoD is accom panied 
by the suppression of the nonmuscle phenotype of that cell. 
This is a specifi  c example of a general feature of cell differ-
entiation; establishing a new cellular phenotype requires sup-
pression of features associated with the prior phenotype or other 
related phenotypes.
Although the activation of skeletal muscle gene expression 
by MyoD has been intensively studied, very little is known about 
the ability of MyoD to suppress gene expression. Several studies 
have indicated that MyoD can form repressive complexes, and 
these complexes have been suggested to be a mechanism of 
  directly recruiting transcriptional repressors to specifi  c promoters. 
For example, MyoD has been shown to recruit HDAC1 to the 
Myog promoter in myoblasts with an associated hypoacetylation 
of regional histones (Mal et al., 2001; Mal and Harter, 2003), 
and a similar MyoD-mediated recruitment of the Sir2 HDAC to 
suppress gene expression has been previously described (Fulco 
et al., 2003). When cells differentiate, MyoD has been shown 
to recruit histone acetylases and chromatin-  remodeling com-
plexes to some of the same promoters shown to be suppressed 
by HDAC recruitment in myoblasts (de la Serna et al., 2001, 
2005;   Bergstrom et al., 2002), suggesting that a switch between a 
repressive complex and an activating complex occurs at the ini-
tiation of terminal differentiation. In addition, components of the 
repressive Polycomb complex have been shown to be associated 
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erminal differentiation of distinct cell types requires 
the transcriptional activation of differentiation-
  speciﬁ  c genes and the suppression of genes asso-
ciated with the precursor cell. For example, the expression 
of  utrophin ( Utrn) is suppressed during skeletal muscle 
  differentiation, and it is replaced at the sarcolemma by the 
  related dystrophin protein. The MyoD transcription factor 
directly activates the expression of a large number of skeletal 
muscle genes, but also suppresses the expression of many 
genes. To characterize a mechanism of MyoD-mediated 
suppression of gene expression, we investigated two genes 
that are suppressed in ﬁ   broblasts converted to   skeletal 
muscle by MyoD, follistatin-like 1 (Fstl1) and Utrn. MyoD 
directly activates the expression of a muscle-speciﬁ   c 
  microRNA (miRNA), miR-206, which targets sequences in 
the Fstl1 and Utrn RNA, and these sequences are sufﬁ  cient 
to suppress gene expression in the presence of miR-206. 
These ﬁ  ndings demonstrate that MyoD, in addition to acti-
vating muscle-speciﬁ  c genes, induces miRNAs that repress 
gene expression during skeletal muscle differentiation.
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with repressed muscle genes before   differentiation and replaced 
by MyoD and other activators   during differentiation (Caretti 
et al., 2004). Therefore, there is precedent for a regulated transi-
tion from repressive promoter complexes to activating com-
plexes during skeletal muscle differentiation, and some evidence 
that MyoD can recruit either activators or   repressors to the pro-
moter regions, depending on cellular   context, i.e., whether a cell 
is a replicating myoblast or differentiating myotube.
These developmental transitions can account for a general 
switch from repression to activation, but do not necessarily 
  account for the simultaneous activation and repression of sets 
of genes during MyoD-mediated myogenesis. Our expression 
array study with an inducible MyoD in fi  broblasts showed that 
MyoD activates the expression of several distinct temporal clus-
ters of genes and simultaneously suppresses the expression of 
other gene sets (Bergstrom et al., 2002). In our current study, 
we use this model system of MyoD-mediated myogenesis to 
determine how a single transcription factor simultaneously acti-
vates and suppresses different sets of genes during myogenic 
differentiation. We demonstrate that MyoD directly regulates the 
transcription of microRNA (miRNA) expression that suppresses 
specifi  c targets during myogenic differentiation. In addition, our 
demonstration that a MyoD-induced miRNA targets the Utrn 
RNA and can posttranscriptionally suppress expression through 
this sequence suggests that therapies of Duchenne muscular 
dystrophy based on increasing Utrn expression should   include 
modulation of these posttranscriptional mechanisms.
Results
Previously, we have used microarray studies to show that MyoD 
both induces expression of a large number of genes and simul-
taneously elicits a reduction in the RNA abundance of a subset 
of genes (Bergstrom et al., 2002). To study the mechanism of 
decreased RNA abundance by MyoD, we focused on follistatin-
like 1 (Fstl1). Although Fstl1 does not have a defi  ned biological 
role in muscle physiology, we chose to study this gene because 
it showed a robust decrease in its message during the fi  rst 24 h 
of MyoD induction. As in our previous studies, we used mouse 
embryonic fi  broblasts (MEFs) derived from mice with both the 
endogenous MyoD and Myf5 genes disrupted (M+M cells) that 
contain a constitutively expressed fusion protein between mouse 
MyoD and the hormone-binding domain of the estrogen  receptor 
(MyoD estrogen receptor [MDER]; Hollenberg et al., 1993; 
Bergstrom et al., 2002). Transition of the cells to low-serum dif-
ferentiation medium (DM; see Materials and methods) with the 
addition of β-estradiol synchronously induces MyoD activity 
and initiates differentiation in these cells (Bergstrom et al., 
2002). Consistent with our previous fi  ndings, Fstl1 RNA de-
creased several fold at 24 h after the induction of MyoD activity 
by β-estradiol in the M+M cells, whereas the abundance of 
Myog, which is a downstream transcriptional target of MyoD, 
increased substantially (Fig. 1 A). The decreased abundance of 
Fstl1 RNA in response to MyoD induction and myogenic dif-
ferentiation was also evident in the myoblast cell line C2C12 
that expresses endogenous MyoD and in the 10T1/2 MEF cell 
line that constitutively expresses MDER (Fig. 1 B). Notably, the 
abundance of Fstl1 RNA decreases when MyoD is induced in 
the presence of the protein synthesis inhibitor cycloheximide, 
indicating that MyoD causes a decrease in this RNA in the 
  absence of new protein synthesis (Fig. 2). 
MyoD is a transcription factor with a well-defi  ned DNA-
binding domain and an N-terminal acidic activation domain. To 
determine whether the DNA-binding or activation functions 
of MyoD are necessary to suppress the abundance of Fstl1, we 
tested the activity of two MDER mutant proteins. MDproER 
has an inactivating point mutation (A114P) in the MyoD DNA-
binding domain (Davis et al., 1990), whereas MD∆NER has 
a deletion of the MyoD activation domain (aa 3–56; Tapscott 
et al., 1988). These mutant proteins are expressed at levels com-
parable to wild-type MDER in M+M cells (unpublished data). 
Consistent with prior studies showing that the activation func-
tions of E-protein heterodimers and other recruited factors can 
partially compensate for the absence of the MyoD activation 
Figure 1.  Fstl1 is suppressed in response to MyoD expression. Northern 
blot analysis of Myog and Fstl1 expression at various times after the induc-
tion of MDER expression. RNA was harvested from cells maintained in 
growth medium (0 h) or induced in DM (+ β-estradiol) for the durations 
  indicated. 18S RNA levels were analyzed as a loading control. (A) Analysis 
of Myog and Fstl1 levels in uninduced (0 h, 24 h –β) versus induced 
(24 h + β) M+M MDER cells. (B) Analysis of Fstl1 levels in C2C12, 
10T1/2 MDER, and M+M MDER cells.
Figure 2.  Fstl1 is suppressed in the presence of MyoD and cycloheximide. 
Northern blot analysis of Fstl1 expression after MDER induction. MDER 
  expression was induced by switching to DM with β-estradiol in the absence 
or presence of the protein synthesis inhibitor cycloheximide, as indicated. 
RNA was harvested at 6 or 12 h after treatment with β-estradiol and/or 
cycloheximide, as indicated. Fstl1 expression was also analyzed in the 
  absence of cycloheximide and β-estradiol (0 h). Myog RNA levels were 
analyzed as a positive control for MDER activity and cycloheximide function. 
18S RNA levels were analyzed as a loading control.MYOD-MEDIATED GENE REPRESSION • ROSENBERG ET AL. 79
domain on many promoters (Berkes et al., 2004), we found that 
MD∆NER had a modest but discernable effect on Fstl1 mRNA 
levels (Fig. 3, compare lanes 9 and 10), whereas the induction 
of the DNA binding–defi  cient MDproER mutant did not affect 
the abundance of Fstl1 (Fig. 3, compare lanes 7 and 8).  Together, 
these data suggest that DNA binding by MyoD is required to 
  diminish the abundance of Fstl1.
We next used chromatin immunoprecipitation (ChIP) to 
determine whether MyoD was down-regulating Fstl1 through 
direct binding to regulatory regions. We identifi  ed conserved 
regions within 5 kb of the promoter and used primers targeted 
to these regions (Fig. S1, available at http://www.jcb.org/cgi/
content/  full/jcb.200603039/DC1); however, because of the size 
of the fragmented DNA for the ChIPs it is likely that we effec-
tively screened the entire region 2.5 kb upstream of the  promoter. 
Using antisera to the MyoD protein, we looked for enrichment 
of MyoD at the Fstl1 regulatory regions, compared with  negative 
(IgH) and positive (Myog) internal controls where we have 
  previously determined MyoD binding (Bergstrom et al., 2002; 
Berkes et al., 2004; Penn et al., 2004). ChIP assays showed 
  robust MyoD binding at the Myog regulatory region at 24 h after 
MyoD induction, but none of the regions in the   vicinity of the 
Fstl1 promoter showed enrichment relative to the IgH internal 
negative control (Fig. S1), indicating that MyoD was not  directly 
binding near the promoter of the Fstl1 gene.
To determine whether RNA transcription is necessary for 
MyoD to decrease the abundance of Fstl1 RNA, we treated cells 
with α-amanitin, which, at low concentrations, is an RNA poly-
merase II inhibitor (Wieland and Faulstich, 1978). At doses of 
α-amanitin that are suffi  cient to prevent the transcription of 
MyoD target genes, we found that Fstl1 RNA was no longer 
down-regulated upon MyoD induction (Fig. 4). 
These results indicate that MyoD decreases the abundance 
of Fstl1 in a manner that requires DNA binding and transcrip-
tion, but not protein translation, and is consistent with MyoD-
regulated expression of a regulatory RNA, such as a miRNA 
or siRNA, which posttranscriptionally regulates the abundance 
of the Fstl1 mRNA. Although in many cases miRNAs block 
translation, RNA degradation can also be induced by miRNA 
(for review see Ambros, 2004; Yekta et al., 2004). We used 
the miRanda algorithm to identify several miRNAs that are 
  predicted to potentially bind sites in Fstl1 (John et al., 2004). 
Within this candidate set of miRNAs, Northern blot analysis 
demonstrated that the abundance of miR-206 was dramati-
cally up-regulated by the induction of MyoD activity (Fig. 5). 
Up-regulation of miR-206 was dependent on active MyoD, as 
cells that did not express MDER did not show miR-206 expression 
(Fig. S2, available at http://www.jcb.org/cgi/content/full/jcb.
200603039/DC1). These data are consistent with recently pub-
lished studies indicating an up-regulation of miR-206 in differ-
entiated C2C12 myoblasts (Chen et al., 2006; Rao et al., 2006). 
In addition, miR-206 was not induced by the MDproER  mutation 
in the DNA-binding domain (Fig. 5 C).
The locus encoding mmu-miR-206 is on chromosome 1 
and the 5′ end of the pre–miR-206 closely coincides with the 
5′ end of a longer transcript (AK132542). A conserved E box is 
near the predicted transcription start of the putative miR-206 
hairpin and the AK132542 transcript. ChIP assays show robust 
MyoD binding to this putative regulatory region of miR-206 
(Fig. 6). (In addition, while this manuscript was under review, 
Rao et al., 2006 identifi  ed miR-206 as a MyoD target by ChIP.) 
Northern and RT-PCR analysis demonstrate that the longer 
AK132542 transcript is also induced by MyoD (Fig. S3, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200603039/DC1), 
suggesting that a larger RNA might be transcribed and processed 
to produce miR-206. It is interesting to note that the miR-133b 
sequence is also contained in the AK132542 transcript. miR-133 
has recently been shown to be induced during differen  tiation of 
C2C12 muscle cells (Chen et al., 2006; Rao et al., 2006), and 
miR-133 is induced by MyoD together with miR-206 in M+M 
MDER cells (unpublished data). Therefore, it is   possible that the 
induction of AK132542 by MyoD might lead to the production 
Figure 3.  MyoD DNA-binding and activation activities are required for 
repression of Fstl1. Northern blot analysis of Fstl1 expression in M+M cells 
either lacking MyoD expression (pBABE), or expressing MDER (wild type), 
MDproER (DNA-binding domain mutant), or MD∆NER (activation domain 
mutant). RNA was harvested from cells maintained either in growth   medium 
(0 h), or in DM for 24 h with or without the addition of β-estradiol, as 
  indicated. 18S RNA levels were analyzed as a loading control.
Figure 4.  Suppression of Fstl1 in response to MDER induction requires 
transcription. Northern blot analysis of Fstl1 expression in the absence 
or presence of the transcriptional inhibitor α-amanitin. RNA was harvested 
from cells maintained either in growth medium (0 h) or in DM with β-estradiol 
for 12 h, in the presence of 0, 20, 40, 80, or 100 μg/ml α-amanitin, as 
indicated. 18S RNA levels were analyzed as a loading control. (A) Analysis 
of Fstl1 and M-cadherin expression in M+M MDER cells. α-Amanitin was 
added to the cells 15 min before the addition of β-estradiol, except in 
lane 7, where the reagents were added simultaneously. M-cadherin expres-
sion was analyzed as a positive control for MDER activity and α-amanitin 
  function. (B) Analysis of Fstl1 expression in M+M pBABE cells, which do 
not express MDER.JCB  80
of both miR-206 and -133. Our data indicate, therefore, that 
MyoD directly binds the promoter region of the miR-206 pre-
cursor, and the binding is correlated with trans  cription of a longer 
precursor RNA and the appearance of the mature miR-206.
To determine whether the miR-206 can target the 3′UTR 
of the Fstl1 gene, we cloned three copies of the putative target 
sequence (Fig. 7 A) into the 3′ UTR of a luciferase reporter 
gene (CS2-luc-Fstl1) and, as a control, we cloned similar multi-
mers of the target sequence containing mutations that should 
disrupt miR-206 binding (MutA and MutB). Compared with the 
parent vector, the expression of the CS2-luc-Fstl1 reporter was 
signifi  cantly suppressed by MyoD induction, whereas the MutA 
and MutB were not suppressed by MyoD (Fig. 7 B). These data 
suggest that MyoD activation results in specifi  c   repression 
  targeted to the Fstl1 3′UTR. To show a direct effect of miR-206 
on the CS2-luc-Fstl1 reporter, we cotransfected cells with a 
miR-206 hairpin precursor (pre–miR-206), which is processed 
by the M+M MDER cells to produce the mature, 22 nucleotide 
miR-206 (Fig. 7, C and D). Consistent with the effect of MDER 
induction, we see a decrease in CS2-luc-Fstl1 reporter activity, 
but not in MutA or MutB reporter activity, when cells are co-
transfected with pre–miR-206. Together, these data demonstrate 
that the conserved sequence motif in the 3′-UTR of Fstl1 is tar-
geted by miR-206. To confi  rm that miR-206 can target the Fstl1 
mRNA, and to develop a method to identify additional miR-206 
targets, we used a miR-206   oligonucleotide as a primer in a re-
verse transcriptase reaction to see if it would prime the Fstl1 
mRNA, as detected by subsequent PCR. An oligonucleotide of 
the miR-206   sequence primed fi  rst strand synthesis from the 
Fstl1 mRNA, whereas neither desmin nor Timm17b (a constitu-
tively expressed control RNA) were primed by miR-206 (Fig. 8). 
Cloning and   sequencing the miR-206–primed cDNA confi  rmed 
that miR-206 binds to the predicted target site in Fstl1 and 
to an additional site further 3′ in the RNA, suggesting that 
  multiple miR-206–binding sites might exist in the Fstl1 3′ UTR 
(unpublished data). In considering the aforementioned data, we 
conclude that MyoD down-regulates Fstl1 by transcriptionally 
activating the miR-206 gene, which posttranscriptionally regu-
lates Fstl1 through the conserved motif in its 3′UTR sequence.
Although little is known about the potential function of 
Fstl1 in myogenesis, other predicted targets of miR-206 have 
been extensively studied. For example, Utrn is a predicted target 
of miR-206 (http://microrna.sanger.ac.uk/). Consistent with the 
predicted interaction, a miR-206 oligonucleotide can prime the 
Utrn mRNA in a reverse transcriptase reaction (Fig. 8), and clon-
ing and sequencing of the miR-206–primed cDNA confi  rmed 
that the miR-206 oligonucleotide binds to the predicted target 
site in Utrn (not depicted). The predicted miR-206–binding site 
in Utrn is highly conserved in mouse, human, and dog and shares 
the same “seed” sequence as the miR-206 site in Fstl1 (Fig. 9 A). 
In our model system of MyoD-induced myogenesis, there is a 
small decrease in the abundance of the Utrn mRNA after 12 h of 
MyoD induction (Fig. 9 B) and a more marked decrease in the 
abundance of the protein at 48 and 96 h of MyoD induction, 
which is dependent on the presence of an active MyoD (Fig. 9 C, 
compare the pBABE control cells with the MDER cells). A CS2-
luciferase reporter containing a multimer of the putative 
miR-206–binding site from the Utrn mRNA shows substantial 
inhibition when cotransfected with the pre–miR-206 construct 
(Fig. 9 D), demonstrating that this site is indeed targeted by 
miR-206. Another muscle-specifi  c miRNA, miR-1, has high 
Figure 5.  miR-206 is up-regulated in response 
to MyoD expression. Northern blot analysis of 
miRNA expression. Total RNA was harvested 
from M+M cells that were maintained either 
in growth medium (0 h), or in DM with β-estra-
diol for 24 h, as indicated. M+M cells 
  expressed wild-type MDER, MD∆NER, or MD-
proER, as indicated. miRNA was detected 
  using radioactive end-labeled oligonucleotide 
probes complementary to the mature miRNA 
sequence. The sizes of the mature (22 nt) and 
pre-miRNA (73 nt) transcripts are indicated. 
A and B consist of the same RNA probed se-
quentially for miR-206 and -16. Radiolabeled 
10-bp DNA ladder is shown as a size  standard. 
(A) Analysis of miR-16 expression in M+M MDER cells. (B) Analysis of miR-206 expression in M+M MDER cells. (C) Analysis of miR-206 expression 
in M+M MDER, M+M MD∆NER, and M+M MDproER cells.
Figure 6.  MyoD binding is enriched at the miR-206 locus. ChIP analysis 
of MyoD binding. (A) Schematic representation of the genomic location 
of the putative miR-206 hairpin and chromatin IP amplicon. Predicted 
miR-206 hairpin is represented as a gray rectangle. The conserved E box 
that is the putative MyoD-binding site in the region is indicated. Positions of 
the primers used to produce the ChIP amplicon are represented as arrows. 
(B) ChIP assay. Chromatin from cells either maintained in growth medium 
(0 h) or in DM for 24 h (24 h +β) was immunoprecipitated with an anti-
body against MyoD and interrogated by duplex PCR. A genomic DNA 
  titration was performed to indicate relative PCR efﬁ   ciencies based on 
equivalent template amounts.MYOD-MEDIATED GENE REPRESSION • ROSENBERG ET AL. 81
 sequence homology to miR-206, and it is also induced in the M+M 
MDER cells (unpublished data). Transfection of pre–miR-1 had 
a signifi  cant, but more modest, suppression of the CS2–luc–Utrn 
construct, and cotransfection of both pre–miR-206 and -1 did not 
show synergistic activity. Therefore, we conclude that the induc-
tion of miR-206 by MyoD can alter the stability and/or the trans-
lation of subpopulations of RNAs, some of which are biologically 
relevant to the process of terminal myogenic differentiation. 
  Furthermore, the demonstration that at least a portion of the sup-
pression of Utrn expression occurs posttranscriptionally suggests 
specifi  c therapies aimed at increasing or maintaining Utrn ex-
pression in Duchenne muscular dystrophy.
Discussion
Expression of MyoD in a wide variety of cell types is suffi  cient to 
activate the program of skeletal muscle differentiation (Tapscott, 
2005). Although different sets of genes are expressed in specifi  c 
temporal patterns during muscle differentiation, we have shown 
that MyoD directly binds to the regulatory regions of genes ex-
pressed both early and late in the program (Bergstrom et al., 2002). 
Temporal patterning is achieved through a feed-forward mecha-
nism, where transcription factors activated by MyoD early in the 
myogenic program feed-forward to cooperate with MyoD to acti-
vate genes expressed later in the program (Penn et al., 2004). In 
this manner, a single transcription factor can directly orchestrate 
the temporal program of gene activation during skeletal muscle 
differentiation. Our fi  ndings in this study demonstrate that the same 
transcription factor that has a central role in activating muscle-
 specifi  c genes simultaneously induces miRNAs that repress gene 
expression during myogenic differentiation. Specifi  cally, we 
  demonstrate that MyoD acts as a transcriptional activator of the 
miR-206 pre–miRNA transcript and the induced high levels of the 
mature miR-206 result in the down-regulation of specifi  c target 
genes, such as Fstl1 and Utrn.
We chose to investigate the regulation of Fstl1 because it 
was identifi  ed as a suppressed RNA in our time-course study of 
MyoD-regulated genes (Bergstrom et al., 2002). Fstl1 was origi-
nally identifi  ed as TSC-36 (TGF-β stimulated clone 36) in a screen 
for genes induced by TGF-β in mouse osteoblasts, and was ob-
served to have some amino acid homology to Fst (Shibanuma et al., 
1993). It is not currently known whether Fstl1 has overlapping 
or distinct functions from Fst, however, the different developmental 
expression patterns of these two genes (de Groot et al., 2000) 
Figure 7.  miR-206 targets the Fstl1 3′UTR. (A) Schematic representation of the CS2-luciferase constructs containing multimers of the putative miR-206-
  binding site in the 3′ UTR of Fstl1. The nucleotides targeted by miR-206 are indicated by a boxed area. The sequences from mouse and human Fstl1 are 
shown to indicate the evolutionary conservation of this region. The murine sequence was multimerized and inserted into the 3′UTR of the luciferase gene. 
The mutations in the miR-206 target sequence that distinguish the MutA and MutB constructs are shown. (B) Induction of MyoD-ER expression represses 
CS2-luc-Fstl1 activity. Cells were transfected with CS2-luc, CS2-luc-Fstl1 (WT), CS2-luc-MutA, or CS2-luc-MutB. CS2-β-gal was cotransfected as an internal 
control. After transfection, cells were switched to DM with β-estradiol. Control cells were not treated with β-estradiol. (C) Exogenous pre–miR-206 targets 
CS2-luc-Fstl1. Cells were cotransfected with pre–miR-206 or pre–miR-Negative Control (NC) and the reporter constructs (MutA and MutB were not tested 
with pre–miR-NC, as they showed no response to pre–miR-206). Vector alone cells were not cotransfected with pre–miRs. (D) Exogenous pre–miR-206 is 
processed to produce mature miR-206 in M+M MDER cells. MiRNA Northern blot analysis of miR-206. Total RNA from M+M MDER cells transfected with 
25 nM pre–miR-206 (lane 3) was compared with endogenous miR-206 from nontransfected cells that had been maintained either in growth medium (lane 2) 
or in DM with β-estradiol (lane 1). The positions of the unprocessed pre–miR-206 and the mature miR-206 are indicated. An ethidium bromide–stained 
  image of the tRNA contained in each lane serves as a loading control. A radiolabeled 10-bp DNA ladder was used as a size standard (not depicted).JCB  82
  suggest   distinct biological functions. Additionally, a functional 
  domain   important for Fst activity, the activin-binding domain 
(Wang et al., 2000), is not conserved in Fstl1. Therefore, although 
Fst has been shown to antagonize activin and myostatin during 
myogenesis (Amthor et al., 2004), the role of Fstl1 in this process 
remains unknown.
In contrast, the decreased expression of Utrn protein in 
skeletal muscle is thought to be an important process in differ-
entiation. During muscle differentiation, dystrophin, which is 
a Utrn paralog, replaces the Utrn protein in the dystrophin-
  associated glycoprotein complex. Importantly, the loss of dys-
trophin protein is the etiologic basis for Duchenne muscular 
dystrophy. The demonstration that constitutive expression of 
Utrn protein in the skeletal muscle of transgenic mice (Tinsley 
et al., 1996) can partially compensate for the loss of dystrophin 
has led to   attempts to transcriptionally induce Utrn gene expres-
sion in mature muscle cells, in the hope that Utrn up-regulation 
might prove therapeutic to DMD patients. Our demonstration 
that miR-206 can suppress expression posttranscriptionally 
through a sequence in the Utrn RNA suggests that therapies 
based on posttranscriptional regulation of the Utrn RNA should 
also be explored.
Since the initial discovery that lin-4 acts as a regulatory 
RNA in Caenorhabditis elegans (Lee et al., 1993), there has been 
growing interest in understanding how miRNAs, acting post-
transcriptionally, interface with well-characterized transcriptional 
regulatory networks to enforce precise regulation of gene expres-
sion programs in animals (Ambros, 2004). As a result, we are 
  beginning to learn that miRNAs play important roles in embry-
onic development and cell fate (for review see Pasquinelli et al., 
2005). Several groups have demonstrated tissue-specifi  c distribu-
tion of miRNAs in developing embryos and adult animals  (Lagos-
Quintana et al., 2002; Mansfi  eld et al., 2004; Hornstein et al., 
2005). Further, it seems that several miRNAs act in the specifi  ca-
tion of cell lineage. For example, miR-181, -223, and -142 are 
preferentially expressed in mouse hematopoietic tissues, where 
mir-181 specifi  es the B cell lineage and miR-223 promotes gran-
ulocyte differentiation (Chen et al., 2004; Fazi et al., 2005). 
  Recently, the role of miRNAs in skeletal and cardiac muscle 
  biology has been the focus of intense interest.
To date, three muscle-specifi  c miRNAs have been identifi  ed: 
miR-1, -133, and -206. miR-1 expression is strictly limited to car-
diac and skeletal muscle in Drosophila melanogaster,   zebrafi  sh, 
and mouse, although species-specifi  c variations in expres  sion 
patterns have been noted (Biemar, et al., 2005; Brennecke et al., 
2005; Kwon et al., 2005; Sokol and Ambros, 2005; Wienholds 
and Plasterk, 2005; Zhao et al., 2005). Expression of miR-1 is 
up-regulated in response to differentiating signals in cardiac and 
skeletal muscle in vivo and differentiated myoblasts in vitro, and 
it has been shown to be activated by several factors, including 
SRF, Twist, myocardin, and Mef2 (Kwon et al., 2005; Sokol 
and Ambros, 2005; Zhao et al., 2005).   Another muscle-specifi  c 
miRNA, miR-133, has been shown to promote proliferation of 
myoblasts by antagonizing SRF (Chen et al., 2006). Recently, 
a role for miR- 181 in muscle differentiation and regeneration 
was also described (Naguibneva et al., 2006). We now show that 
miR-206 is a direct transcriptional target of MyoD and functions 
to suppress targets during muscle differentiation.
Although our study has focused on a single miRNA and its 
targets, we assume that multiple miRNAs will be similarly regu-
lated by MyoD. Similarly, it is likely that the related myogenic 
bHLH proteins (Myf5, Myog, and Mrf4) will also induce miR-206. 
Indeed, our recent ChIP study identifi  ed four additional miRNA 
promoter regions bound by MyoD: miR-100, -138-2, -191, 
and -22 (Cao et al., 2006), and a study published while this 
  paper was under review showed that MyoD and Myog bind the 
putative regulatory regions of miR-206, -1, and -133 (Rao et al., 
2006). Because many of the targets of miRNAs can be trans-
lationally inhibited in the absence of RNA degradation, the ex-
pression array studies we used as the basis for investigating 
the regulation of Fstl1 are likely underestimating the extent of 
genes suppressed during myogenesis. Additionally, because it has 
been demonstrated that transfection of a single miRNA (e.g., 
miR-1) into HeLa cells decreases nearly 100 mRNA transcripts 
(Lim et al., 2005), it seems likely that future studies will show 
multiple   additional genes to be targeted by miRNAs in response 
to MyoD.
Materials and methods
Cell culture
MEFs null for both MyoD and Myf5 (M+M cells) were infected with a 
  retrovirus containing the pBABE vector expressing a puromycin-resistance 
gene and MDER (Hollenberg et al., 1993). Mutant MDER proteins 
Figure 8.  Fstl1 and Utrn mRNA contain miR-206 target sites. RT-PCR analy-
sis of Fstl1 and Utrn using a miR-206 oligo to prime ﬁ  rst-strand synthesis. 
  After collection of RNA from M+M MDER cells either maintained in growth 
medium (0 h −β) or cultured in DM with β-estradiol (48 h +β), reverse tran-
scription was performed in which either a DNA oligo corresponding to 
miR-206, a random hexamer oligo mixture (positive control), or no primer 
(negative control) was used. PCR was subsequently performed with primers 
speciﬁ  c for Fstl1, Utrn, Timm17b, and desmin, as indicated. Timm17b and 
Desmin are not predicted targets of miR-206 and are used to demonstrate 
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(MDproER and MD∆NER) were constructed in the same vector context. 
Control cells (M+M pBABE) were infected with virus containing only vector 
and selectable marker. Cells were maintained in growth medium, which 
consisted of DME containing 1% L-glutamine and 10% bovine calf serum 
(Hyclone). Infected cells were selected in 1.2 μg/ml puromycin. To induce 
expression of MDER, cells were switched to DM, which consisted of DME 
containing 1% L-glutamine, 0.5% horse serum, 10 μg/ml insulin, 10 μg/ml 
transferrin, and 10
−7 M β-estradiol.
Transient transfection and luciferase assay
All transient transfection/luciferase assays were performed in triplicate on 
35-mm tissue culture dishes (Corning). For transfections, each plate was 
seeded with 10
5 cells and incubated overnight at 37°C. Cells were trans-
fected using Superfect reagent (QIAGEN) as speciﬁ  ed by the   manufacturer. 
The constructs used for transfections contained the indicated regions of 
Fstl1 or Utrn 3′UTR sequence inserted 3′ of the ﬁ  reﬂ   y luciferase gene, 
under the control of the CMV promoter in the CS2 vector background. 
Each plate was transfected with 100 ng of CS2-luc reporter vector and 
2 μg of empty CS2 vector. Where indicated, cells were cotransfected with 
pre–miR-206, -1, or -Negative Control #1 (Ambion) to a ﬁ  nal concentration 
of 25 nM, and luciferase activity was measured 24 h after   transfection. 
Where indicated, MDER activity was induced in transfected cells at 
16–24 h after transfection by switching cells to DM with 10
−7 M β-estradiol 
  (uninduced cells were switched to DM without β-estradiol), and luciferase 
activity was measured at 24 h after induction. For all experiments, cells were 
cotransfected with 200 ng of CS2-β-gal, and assayed for β-galactosidase 
activity as an internal control for transfection efﬁ   ciency using the MUG 
assay. Luciferase assays and MUG assays were performed as previously 
described (Bergstrom and Tapscott, 2001), using AutoLumat LB 953 
(BERTHOLD T  E  C  H  N  O  L  O  G  I  E  S  ) and MicroFluor (Dynatech) instrumentation.
Northern blot analysis
Cultured cells were harvested by scraping, and RNA was prepared using 
the RNEasy kit (QIAGEN). Northern blot analysis was performed according 
to standard techniques, which were previously described (Bergstrom et al., 
2002). Probes were generated by PCR ampliﬁ  cation of cDNA reverse 
  transcribed from total M+M MDER RNA using an oligo-dT primer and 
  SuperScript II (Invitrogen), and were radioactively labeled using Ready-to-
Go DNA labeling beads (GE Healthcare). Images were captured on ﬁ  lm, 
digitized, and if needed, minor linear adjustments in contrast were made 
using Adobe Photoshop software.
miRNA northern blot analysis
Total RNA was prepared using Trizol (Invitrogen) extraction, per the manu-
facturer’s instructions. Trizol puriﬁ  cation was followed by acid phenol ex-
traction to remove any DNA contamination. Each sample contained 20 μg 
RNA. Samples were separated electrophoretically in a 20% polyacryl-
amide/8 M urea/1× TBE gel. RNA was electroblotted onto Nytran SPC 
nylon membrane in 1× TBE at 250 mA for 45 min, and was ﬁ  xed to the 
membrane by UV cross-linking. Blots were hybridized overnight at 35°C in 
Ultrahybe Oligo buffer (Ambion) with radiolabeled oligonucleotide probes 
complementary to the mature miRNA sequences of interest. Images were 
Figure 9.  miR-206 targets the Utrn 3′UTR. (A) The 3′UTR of Utrophin contains an evolutionarily conserved miR-206 target sequence. (left) Alignment 
  between the miR-206 target sites of Mus musculus Fstl1 and the miR-206 target sites of Utrophin from M. musculus, Homo sapiens, and Canis familiaris. 
The highly conserved, 8-bp “seed” sequence for miR-206 target recognition is indicated by a box. (right) Alignment between the respective miR-206 target 
sites and miR-206. (B) Real-time PCR analysis of utrophin expression in M+M MDER cells. RNA was harvested from cells incubated for up to 96 h in DM 
in the presence or absence of β-estradiol, as indicated, and the relative abundance of utrophin transcripts was measured using Timm17b transcript abundance 
as a reference. (C) Western blot analysis of utrophin in M+M MDER cells. Lysates were prepared from M+M pBABE cells (lacking MDER) or M+M MDER 
cells that had been cultured for up to 96 h in DM in the presence or absence of β-estradiol, as indicated. Each sample contained 70 μg total protein, 
as   determined by BCA assay. Samples were subjected to SDS-PAGE and immunoblotted with anti-utrophin antibody. The samples were subsequently 
immuno  blotted with anti-Hsp70 antibody as a loading control. (D) Exogenous pre–miR-206 targets the CS2–luc–Utrn reporter in the absence of MDER 
  expression. The miR-206 target sequence in the 3′UTR of Utrn was multimerized and inserted into the 3′UTR of the luciferase gene, as shown. Cells were 
cotransfected with pre–miR-206, -1 (alone and in combination with pre–miR-206), or -Negative Control (NC) reagent and the reporter constructs, as indi-
cated. Vector alone cells were not cotransfected with pre–miR reagent. Asterisk indicates that the CS2-luc construct was not tested with the pre–miR-NC 
  reagent, as it did not respond to pre–miR-1 or pre–miR-206.JCB  84
captured on ﬁ   lm, digitized, and if needed, minor linear adjustments in 
  contrast were made using Photoshop software (Adobe).
ChIP assay
ChIP analysis was performed as previously described (Filippova et al., 
2001; Penn et al., 2004). Precipitations from 750–1,000 μg M+M MDER 
cell lysate were incubated overnight at 4°C with 5 μl anti-MyoD antiserum 
(Tapscott et al., 1988). Duplex PCR was performed by coamplifying test con-
trol regions from MyoD target genes with an internal control region from the 
IgH enhancer. Ampliﬁ  cation reactions included 
32P-dCTP for incorporation 
into PCR product that was then detected and quantiﬁ  ed by PhosporImager 
analysis using ImageQuant software (Molecular Dynamics). For input sam-
ples, a titration of 0.03–3.00 ng of genomic DNA was used as a template 
for duplex PCR to establish relative ratios of PCR product in the absence of 
any asymmetry in target abundance. For MyoD IPs, 5% of the IP sample was 
used per reaction and ampliﬁ  ed over 32 PCR cycles. Results were analyzed 
for enrichment at the muscle-speciﬁ  c target sequence relative to the target 
  sequence/control sequence ration established using input DNA sample. PCR 
linearity was conﬁ  rmed by titrating the input DNA over a 30-fold range. 
  Efﬁ  ciency of MyoD IP was conﬁ  rmed by analysis of MyoD enrichment at the 
Myog promoter, as described previously (Bergstrom et al., 2002).
Primer extension
Total RNA was collected from M+M MDER cells cultured in either growth 
medium (0 h) or DM with β-estradiol (48 h) using the RNEasy kit (QIAGEN). 
RT-PCR was performed by standard methodology using 0.5 ug of total 
RNA per sample. For reverse transcription, a DNA oligonucleotide cor-
responding to mir-206 (5′-T  G  G  A  A  T  G  T  A  A  G  G  A  A  G  T  G  T  G  T  G  G  -3′) was used 
as a primer, a sample primed with random hexamer was used as a 
positive control, and an unprimed sample was used as a negative control. 
Thermocycler conditions for reverse transcription with random hexamer 
primers were as follows: 45°C/15 min, 50°C/15 min, 55°C/15 min, and 
75°C/15 min. For the miR-206–primed samples, higher temperatures were 
used to achieve higher target speciﬁ  city as follows: 50°C/45 min, 55°/15 min, 
60°C/15 min, and 75°C/15 min. The thermocycler conditions for the 
unprimed negative control samples were the same as for the miR-206–
primed samples. After reverse transcription, all samples were treated with 
RNaseH for 1 h at 37°C before performing PCR. For the detection of cDNAs 
by PCR, 28 cycles were performed for Fstl1 and Utrn; 26 cycles for desmin 
and 29 cycles for Timm17b. For detection of Fstl1, the primer sequences 
were as follows: Fstl1-F, 5′-T  C  A  C  A  G  C  A  G  C  A  A  T  G  C  C  A  T  C  A  T  C  A  A  -3′; Fstl1-R, 
5′-G  A  T  T  G  G  C  C  A  A  C  A  G  A  C  A  C  T  G  C  A  G  C  T  A  -3′. For the detection of Utrn, 
the primer sequences were as follows: Utrn-F, 5′-TGC C  A  A  T  C  C  C  A  A  G  A  C  C-
C  A  T  T  C  A  A  C  ; and Utrn-R, 5′-T  C  A  G  T  G  A  C  A  A  A  T  G  C  T  T  T  A  C  C  A  C  C  T  C  C  A  -3′.
For the detection of desmin, the primer sequences used were as 
follows:  desmin-F:  5′-C  T  C  G  A  G  C  A  G  G  C  T  T  C  G  G  T  A  C  C  -3′;  desmin-R:  5′-C  T  T  G  G-
  C  G  C  A  G  C  G  C  A  T  C  G  T  T  G  -3′.
For the detection of Timm17b, the same primer set was used as for 
real-time PCR (see next section). PCR products were resolved on 1% aga-
rose gels and stained with SYBR gold (Invitrogen).
Quantitative real-time PCR
Cultured cells were harvested by scraping and RNA was prepared using the 
RNEasy kit (QIAGEN). Real-time PCR was performed using TaqMan universal 
PCR mix reagent, according to the manufacturer’s instructions (Applied 
Biosystems). For detection of utrophin, the primers and probe sequences 
were as follows: Utrn-F primer, 5′-G  G  C  A  G  A  A  C  G  A  A  T  T  C  A  G  T  G  A  C  -3′; 
Utrn-R primer, 5′-A  T  C  A  C  T  G  A  T  G  G  G  T  G  G  T  T  T  C  C  -3′; and Utrn probe, 5′-C  C-
A  A  A  T  G  G  A  T  A  A  A  C  G  C  T  C  G  A  T  T  T  T  C  C  A  -3′.
For detection of Timm17b, the primers and probe sequences 
were as follows: Timm17b-F primer, 5′-T  G  T  C  A  T  T  G  G  T  G  G  T  G  G  A  G  T  C  T  -3′; 
Timm17b-R primer, 5′-A  C  T  G  C  A  A  A  G  C  T  T  C  C  T  C  C  A  A  T  -3′; and Timm17b 
probe, 5′-TGCTGTGAGGATCCGGGCAC-3′.
Real-time PCR was performed on an Sequence Detection System 
  instrument (ABI Prism 7900HT; Applied Biosystems), and expression levels 
were quantitated using SDS 2.1 software (Applied Biosystems). Each 
  sample was assayed in triplicate; data represents the mean and SD for the 
triplicates. The relative expression levels of utrophin were normalized to those 
of Timm17b in the same samples.
Western blot
Cultured cells were harvested by scraping, resuspended in RIPA lysis buffer 
with 5% SDS (150 mM NaCl, 10 mM Tris, pH 7.2, 1% Triton X-100, 1% 
deoxycholate, and 5 mM EDTA), and homogenized by repeated manipula-
tion through a 22-gauge needle. Protein concentration for each lysate 
preparation was determined by BCA assay. Samples were concentrated 
by methanol-chloroform extraction (Wessel and Flugge, 1984) and resus-
pended in loading buffer. Each sample analyzed contained 70 μg total 
protein. Samples were electrophoresed on a 6% SDS-PAGE and trans-
ferred to nitrocellulose for 3.5 h at 500 mA. Utrophin was detected using 
goat anti-utrophin (E-16) polyclonal antibody (Santa Cruz Biotechnology, 
Inc.); Hsp70 was detected using mouse anti-Hsp70 monoclonal antibody 
(Stressgen). Images were captured on ﬁ  lm, digitized, and if needed, minor 
linear adjustments in contrast were made using Photoshop software.
Online supplemental material
Fig. S1 shows ChIP analysis of MyoD binding at the Fstl1 promoter, where 
MyoD binding was not detected. Fig. S2 shows that M+M pBABE cells 
(M+M cells that do not express MDER) do not express miR-206 upon 
switching to DM. Fig. S3 shows that MyoD induces the expression of 
the AK132542 transcript. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.200603039/DC1.
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